Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Analyse van circulerend tumor-DNA bij patiënten met ‘ALK’-positieve longkanker
dec 2019 | Longoncologie